CytomX’s Probody T-Cell Platform Produces Astellas Pact

Bispecifics collaboration with Astellas May Be Worth $1.6bn For CytomX

Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.  

Antibodies_Cancer
Probody T-cells bind selectively to tumors, minimizing healthy tissue damage • Source: Shutterstock

CytomX Therapeutics Inc. has landed its second strategic bispecifics collaboration, this time with Astellas Pharma Inc. of Japan in a deal potentially worth more than $1.6bn that focuses on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens, for the treatment of cancer.

Under the deal, announced on 23 March, CytomX is eligible for high-single to mid-teen royalties, and may also exercise an...

More from Deals

More from Business